1. Academic Validation
  2. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease

  • J Med Chem. 2015 Feb 12;58(3):1159-83. doi: 10.1021/jm501350y.
Leticia M Toledo-Sherman 1 Michael E Prime Ladislav Mrzljak Maria G Beconi Alan Beresford Frederick A Brookfield Christopher J Brown Isabell Cardaun Stephen M Courtney Ulrike Dijkman Estelle Hamelin-Flegg Peter D Johnson Valerie Kempf Kathy Lyons Kimberly Matthews William L Mitchell Catherine O'Connell Paula Pena Kendall Powell Arash Rassoulpour Laura Reed Wolfgang Reindl Suganathan Selvaratnam Weslyn Ward Friley Derek A Weddell Naomi E Went Patricia Wheelan Christin Winkler Dirk Winkler John Wityak Christopher J Yarnold Dawn Yates Ignacio Munoz-Sanjuan Celia Dominguez
Affiliations

Affiliation

  • 1 Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon, OX14 4RZ, U.K.
Abstract

We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against Other kynurenine pathway Enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

Figures
Products